Huons Meditech, the medical device subsidiary of Huons Group, said it has appointed Ha Chang-woo as its new CEO. The decision was finalized at an extraordinary general shareholders’ meeting and board of directors’ meeting held at the company’s Seongnam headquarters on Friday.

Born in 1973, Ha earned his master’s degree in business administration from Sungkyunkwan University Graduate School of Business.

He brings more than 25 years of experience in the pharmaceutical and medical device industries, having served in leadership roles at CGBio, Hugel, Dongwha Pharmaceutical, Baxter, and Dong-A Pharmaceutical.

Ha is recognized as a sales strategy expert who has overseen both domestic and international operations. During his tenure at CGBio and Hugel, Ha played a key role in expanding the aesthetics business and laying the foundation for global market entry.

“Huons Meditech is a specialized medical device company with differentiated technology and credibility that ensures unique competitiveness in the global market,” Ha said. “We will diversify our revenue base and accelerate overseas expansion to grow into a leading global medical device company.”

Ha added that the company will expand strategic partnerships and increase investment in research and development to strengthen its presence in the rapidly growing aesthetics medical device market.

“Through innovation and growth, we will elevate Huons Meditech into a company that attracts global attention,” he said.

Huons Meditech has recently reinforced its international footprint by obtaining overseas certifications for several products, including the Dermashine series, an electronically controlled drug delivery device.

In August, the company secured CE-MDR certification in Europe for its Dermashine Pro and Dermashine Balance models, a milestone expected to support further expansion into global markets.